The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS)

Elizabeth D Gilley; Abdalla Bowirrat; Ashim Gupta; John Giordano; Catherine A Dennen; Eric R Braverman; Rajendra D Badgaiyan; Thomas McLaughlin; David Baron; Kenneth Blum

doi:10.2174/1389201024666230427111117

The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS)

Curr Pharm Biotechnol. 2023 Apr 27. doi: 10.2174/1389201024666230427111117. Online ahead of print.

Authors

Elizabeth D Gilley^{1

2}, Abdalla Bowirrat³, Ashim Gupta⁴, John Giordano⁵, Catherine A Dennen⁶, Eric R Braverman², Rajendra D Badgaiyan^{7

8}, Thomas McLaughlin², David Baron⁹, Kenneth Blum^{2

5

9}

Affiliations

¹ The Elle Foundation, West Palm Beach, Florida, FL, USA.
² The Kenneth Blum Institute of Behavior & Neurogenetics, Austin, TX, USA.
³ Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel.
⁴ Future Biologics, Lawrenceville, GA, USA.
⁵ The National Institute of Holistic & Addiction Studies, North Miami Beach, FL, USA.
⁶ Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA.
⁷ Department of Psychiatry, Mt. Sinai University School of Medicine, NYC, NY, USA.
⁸ Department of Psychiatry, Long School of Medicine, University of Texas Medical Center, San Antonio, TX, USA.
⁹ Division of Addiction Research & Education, Center for Psychiatry, Medicine, Primary Care (Office of Provost), Western University Health Sciences, Pomona, CA, USA.

PMID: 37102488
DOI: 10.2174/1389201024666230427111117

Abstract

Introduction: In this genomic era of addiction medicine, ideal treatment planning begins with genetic screening to determine neurogenetic antecedents of the Reward Deficiency Syndrome (RDS) phenotype. Patients suffering from endotype addictions, both substance and behavioral, and other mental health/comorbid disorders that share the neurobiological commonality of dopamine dysfunction, are ideal candidates for RDS solutions that facilitate dopamine homeostasis, addressing the cause, rather than symptoms.

Objective: Our goal is to promote the interplay of molecular biology and recovery as well as provide evidence linked to RDS and its scientific basis to primary care physicians and others.

Methods: This was an observational case study with a retrospective chart review in which an RDS treatment plan that utilized Genetic Addiction Risk Severity (GARS) analysis to evaluate neurogenetic challenges was used in order to develop appropriate short- and long-term pharmaceutical and nutraceutical interventions.

Results: A Substance Use Disorder (SUD) treatment-resistant patient was successfully treated utilizing the GARS test and RDS science.

Conclusion: The RDS Solution Focused Brief Therapy (RDS-SFBT) and the RDS Severity of Symptoms Scale (SOS) may provide clinicians with a useful tool for establishing neurological balance and helping patients to achieve self-efficacy, self-actualization, and prosperity.

Keywords: Dopamine Homeostasis; Genetic Addiction Risk Severity (GARS); Genomic Addiction Medicine; Neurogenetics; Precision Medicine; Pro-Dopamine regulation.